Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia

References

• Ries LAG, Smith MA, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995, NIH Pub. No. 99-4649. Bethesda (MD): National Cancer Institute, SEER Program; 1999.
   Google Scholar
• Hunger SP, Loh ML, Whitlock JA, et al. Children's oncology group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:957–963.
   PubMed Web of Science ®Google Scholar
• Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–4489.
   PubMed Web of Science ®Google Scholar
• Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117:238–249.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010;24:320–334.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211–1218.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study–Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31:1202–1210.
   PubMed Web of Science ®Google Scholar
• August KJ, Miller WP, Dalton A, et al. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration. J Pediatr Hematol Oncol. 2013;35:e283–e286.
   PubMed Web of Science ®Google Scholar
• Broome JD. Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature. 1961;191:1114–1115.
   Web of Science ®Google Scholar
• Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;28:97–113.
   PubMed Web of Science ®Google Scholar
• Stams WA, den Boer ML, Beverloo HB, et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood. 2003;101:2743–2747.
   PubMed Web of Science ®Google Scholar
• Stams WA, den Boer ML, Holleman A, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood. 2005;105:4223–4225.
   PubMed Web of Science ®Google Scholar
• Chien WW, Le Beux C, Rachinel N, et al. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. Sci Rep. 2015;5:8068.
   PubMed Web of Science ®Google Scholar
• Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18:1525–1532.
   PubMed Web of Science ®Google Scholar
• Keding RRE. Discontinuation of Elspar®, (asparaginase for injection) 10,000 IU. Deerfield (IL): Lundbeck LLC. Published August 3, 2012. [cited 2016 Jan 30]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM321556.pdf.
   Google Scholar
• Ho DH, Yap HY, Brown N, et al. Clinical pharmacology of intramuscularly administered L-asparaginase. J Clin Pharmacol. 1981;21:72–78.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Jakobsen P, Schroder H, et al. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemother Pharmacol. 2001;48:77–82.
   PubMed Web of Science ®Google Scholar
• Schrey D, Borghorst S, Lanvers-Kaminsky C, et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr Blood Cancer. 2010;54:952–958.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780–1786.
   PubMed Web of Science ®Google Scholar
• Erwinaze® (asparaginase Erwinia chrysanthemi) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc; 2014 Dec [cited 2016 Jan 30]. Available from: http://erwinaze.com/ERWINAZEPI.pdf.
   Google Scholar
• Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014;32:3874–3882.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010;115:1351–1353.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. 2013;122:507–514.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Kirov II, Dreyer ZE, et al. Activity and toxicity of intravenous Erwinia asparaginase following allergy to E. coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63:228–233.
   PubMed Web of Science ®Google Scholar
• Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32:554–563.
   PubMed Web of Science ®Google Scholar
• Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14:E10–E21.
   PubMedGoogle Scholar
• Ben-Shoshan M, Clarke AE. Anaphylaxis: past, present and future. Allergy. 2011;66:1–14.
   PubMed Web of Science ®Google Scholar
• Murphy K, Travers P, Walport M, editors. Janeway's immunobiology. New York, (NY): Garland Science, Taylor & Frances Group, LLC; 2008.
   Google Scholar
• Burke MJ. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. Future Oncol. 2014;10:2615–2627.
   PubMed Web of Science ®Google Scholar
• Shinnick SE, Browning ML, Koontz SE. Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults. J Pediatr Oncol Nurs. 2013;30:63–77.
   PubMed Web of Science ®Google Scholar
• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52:2237–2253.
   PubMed Web of Science ®Google Scholar
• Advani A, Earl M, Douer D, et al. Toxicities of intravenous pegasparaginase (Oncaspar) in adults with acute lymphoblastic leukemia. Blood. 2007;110:2811.
   PubMed Web of Science ®Google Scholar
• Maloney KW, Angiolillo AL, Schore RJ, et al. Association of intravenous (IV) and intramuscular (IM) pegaspargase (PEG) administration with rate of adverse events (AE) in standard risk (SR) acute lymphoblastic leukemia (ALL) children’s oncology group (COG) trials. J Clin Oncol. 2015;33:10035.
   Web of Science ®Google Scholar
• Fernandez CA, Smith C, Yang W, et al. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood. 2015;126:69–75.
   PubMed Web of Science ®Google Scholar
• Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015;56:2273–2280.
   PubMed Web of Science ®Google Scholar
• van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101:279–285.
   PubMed Web of Science ®Google Scholar
• Liu C, Kawedia JD, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. 2012;26:2303–2309.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Schroder H, Jakobsen P, et al. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol. 2001;52:433–437.
   PubMed Web of Science ®Google Scholar
• Asselin BL. The right dose for the right patient. Blood. 2012;119:1617–1618.
   PubMed Web of Science ®Google Scholar
• Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia. 2003;17:1583–1588.
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123:2026–2033.
   PubMed Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Gach A, Wyka K, et al. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med. 2009;9:113–116.
   PubMed Web of Science ®Google Scholar
• Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer. 1982;49:1378–1383.
   PubMed Web of Science ®Google Scholar
• Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1979;1:9–13.
   PubMedGoogle Scholar
• Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96:375–380.
   PubMed Web of Science ®Google Scholar
• Henriksen LT, Harila-Saari A, Ruud E, et al. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. Pediatr Blood Cancer. 2015;62:427–433.
   PubMed Web of Science ®Google Scholar
• Fernandez CA, Smith C, Yang W, et al. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood. 2014;124:1266–1276.
   PubMed Web of Science ®Google Scholar
• Plourde PV, Jeha S, Hijiya N, et al. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer. 2014;61:1232–1238.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54:199–205.
   PubMed Web of Science ®Google Scholar
• Chen SH, Pei D, Yang W, et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther. 2010;88:191–196.
   PubMed Web of Science ®Google Scholar
• Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109:896–904.
   PubMed Web of Science ®Google Scholar
• Wacker P, Land VJ, Camitta BM, et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia. A Children's Oncology Group Study. J Pediatr Hematol Oncol. 2007;29:627–632.
   PubMed Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, et al. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2007;48:931–936.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Schroder H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol. 2002;38:310–316.
   PubMedGoogle Scholar
• Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood. 2000;96:1709–1715.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Beier R, Loning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol. 2001;114:794–799.
   PubMed Web of Science ®Google Scholar
• Vora A, Goulden N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15:809–818.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Stevenson K, Vrooman LM, et al. Randomized comparison of IV PEG and IM E. coli sparaginase in children and adolescents with acute lymphoblastic leukemia: results of the DFCI ALL Consortium Protocol 05-01. Blood. 2011;118:874.
   PubMed Web of Science ®Google Scholar
• Salzer W, Burke MJ, Larsen EC, et al. Incidence of allergic reactions to pegaspargase (PEG) administered intramuscularly versus intravenously (IM vs. IV) in children and young adults with high risk B-lymphoblastic leukemia (HR B-ALL): results of Children's Oncology Group (COG) studies AALL0232/AALL1131. Blood. 2015;126:1303.
   Web of Science ®Google Scholar
• Abbott LS, Zakova M, Shaikh F, et al. Allergic reactions associated with intravenous versus intramuscular pegaspargase: a retrospective chart review. Paediatr Drugs. 2015;17:315–321.
   PubMed Web of Science ®Google Scholar
• Petersen WC Jr., Clark D, Senn SL, et al. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2014;31:311–317.
   PubMed Web of Science ®Google Scholar
• Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatr Blood Cancer. 2012;59:436–439.
   PubMed Web of Science ®Google Scholar
• MacDonald TJ, Kulkarni K, Bernstein M, et al. Significantly higher incidence of allergic reactions for intravenous PEG-asparaginase as compared to intramuscular PEG-asparaginase in children with high risk acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61:016.
   Google Scholar
• Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood. 2012;119:1658–1664.
   PubMed Web of Science ®Google Scholar
• Kurtzberg J, Asselin B, Bernstein M, et al. Polyethylene glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse. A Children's Oncology Group Study (POG 8866). J Pediatr Hematol Oncol. 2011;33:610–616.
   PubMed Web of Science ®Google Scholar
• Morar AS, Schrimsher JL, Chavez MD. PEGylation of proteins: a structural approach. Biopharm Int. 2006;19:32–34.
   Web of Science ®Google Scholar
• Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110:103–111.
   PubMed Web of Science ®Google Scholar
• Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol. 1984;74:36–39.
   PubMedGoogle Scholar
• Armstrong JK, Leger R, Wenby RB, et al. Occurrence of an antibody to poly(ethylene glycol) in normal donors. Blood. 2003;102–556A.
   PubMed Web of Science ®Google Scholar
• Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of an antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2006;8:R12.
   PubMed Web of Science ®Google Scholar
• Ko RH, Jones TL, Radvinsky D, et al. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: a children's oncology group report. Cancer. 2015;121:4205–4211.
   PubMed Web of Science ®Google Scholar
• Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol. 2012;23:x313–x319.
   PubMed Web of Science ®Google Scholar
• Akbayram S, Dogan M, Akgun C, et al. A desensitization protocol in children with L-asparaginase hypersensitivity. J Pediatr Hematol Oncol. 2010;32:e187–e191.
   PubMed Web of Science ®Google Scholar
• Kawahara Y, Morimoto A, Hayase T, et al. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses. J Pediatr Hematol Oncol. 2014;36:e91–e93.
   PubMed Web of Science ®Google Scholar
• Soyer OU, Aytac S, Tuncer A, et al. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. J Allergy Clin Immunol. 2009;123:895–899.
   PubMed Web of Science ®Google Scholar
• Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children's cancer group study CCG-1961. J Pediatr Hematol Oncol. 2004;26:217–226.
   PubMed Web of Science ®Google Scholar
• Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621–629.
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, Tissing WJ, et al. Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase. Haematologica. 2014;99:e102–e104.
   PubMed Web of Science ®Google Scholar
• Ring J, Brockow K, Behrendt H. History and classification of anaphylaxis. Novartis Found Symp. 2004;257:6–16.
   PubMedGoogle Scholar
• Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005;216:106–121.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Szebeni J, Savay S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol. 2003;14:1430–1437.
   PubMed Web of Science ®Google Scholar
• Heitink-Polle KM, Prinsen BH, de Koning TJ, et al. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. JIMD Rep. 2013;7:103–108.
   PubMedGoogle Scholar
• Jaing TH, Lin JL, Lin YP, et al. Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2009;31:955–956.
   PubMed Web of Science ®Google Scholar
• Nussbaum V, Lubcke N, Findlay R. Hyperammonemia secondary to asparaginase: a case series. J Oncol Pharm Pract. 2014;22:161–164.
   PubMedGoogle Scholar
• Tong WH, Pieters R, de Groot-Kruseman HA, et al. Toxicity of very prolonged PEGasparaginase and Erwinia asparaginase courses in relation to asparaginase activity levels with a special focus on dyslipidemia. Haematologica. 2014;99:1716–1721.
   PubMed Web of Science ®Google Scholar
• Jorck C, Kiess W, Weigel JF, et al. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2011;28:3–9.
   PubMed Web of Science ®Google Scholar
• Howard S, Szwiec K, Buddington K, et al. The weaned pig as a model for asparaginase infusion reactions. Pediatr Blood Cancer. 2015;62:698.
   PubMed Web of Science ®Google Scholar
• Steiner M, Attarbaschi A, Kastner U, et al. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia. Pediatr Blood Cancer. 2007;49:640–642.
   PubMed Web of Science ®Google Scholar
• Paulides M, Jung R, Chada M, et al. Prospective longitudinal examination of hyperammonemia during L-asparaginase treatment within 24 hours after administration in childhood lymphoblastic malignancies. J Leuk. 2013;1:117. doi: 10.4172/2329-6917.1000117.
   Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. NIH Publication No. 09-5410; 2010 Jun 14 [cited 2016 May 1]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
   Google Scholar
• Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia. 1998;12:1527–1533.
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135–3143.
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–473.
   PubMed Web of Science ®Google Scholar
• Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007;11:37–42.
   PubMedGoogle Scholar
• Rituxan® (rituximab) [prescribing information]. South San Francisco (CA): Genentech USA, Inc; 2014 [cited 2016 Jan 30]. Available from: http://www.gene.com/download/pdf/rituxan_prescribing.pdf.
   Google Scholar
• Erbitux® (cetuximab) [prescribing information]. Indianapolis (IN): Eli Lilly and Company; Oct 2015 [cited 2016 Jan 30]. Available from: http://uspl.lilly.com/erbitux/erbitux.html.
   Google Scholar
• Matoori S, Leroux J-C. Recent advances in the treatment of hyperammonemia. Adv Drug Deliv Rev. 2015;90:55–68.
   PubMed Web of Science ®Google Scholar
• Bleyer A, Asselin BL, Koontz SE, et al. Clinical application of asparaginase activity levels following treatment with pegaspargase. Pediatr Blood Cancer. 2015;62:1102–1105.
   PubMed Web of Science ®Google Scholar
• Benitez L, Perissinotti AJ, Santarossa M, et al. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. Pediatr Blood Cancer. 2015;62:1115.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109:2744–2750.
   PubMed Web of Science ®Google Scholar